Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

Authors :: Rashidi, Armin
Oak, Eunhye
Carson, Kenneth R.
Wagner-Johnston, Nina D.
Kreisel, Friederike
Bartlett, Nancy L.
Source :: Leukemia & Lymphoma; May2016, Vol. 57 Issue 5, p1191-1193, 3p
Publication Year :: 2016
Abstract: A letter to the editor is presented related to the article that studies the outcome of Rituximab-based chemoimmunotherapy using rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP).

Full Text Access

Tools